Wellington Management Group LLP Acquires New Shares in Metsera Inc. $MTSR

Key Points

• Wellington Management Group LLP has invested approximately $65.4 million in Metsera Inc. by acquiring 2,401,991 shares, representing a 2.29% ownership stake.
• Metsera's recent performance showed an EPS of ($0.66) in its quarterly earnings report, with its stock trading between a 52-week low of $12.30 and a high of $47.40.
• Equity research analysts have a positive outlook on Metsera, with an average rating of "Buy" and target prices ranging from $55.00 to $65.00.

Wellington Management Group LLP acquired a new stake in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,401,991 shares of the company's stock, valued at approximately $65,382,000. Wellington Management Group LLP owned about 2.29% of Metsera at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. American Century Companies Inc. acquired a new position in shares of Metsera in the 1st quarter valued at $7,791,000. Nuveen LLC acquired a new stake in Metsera during the 1st quarter worth approximately $553,000. Invesco Ltd. purchased a new position in Metsera in the first quarter valued at approximately $271,000. Deutsche Bank AG acquired a new position in Metsera during the first quarter valued at approximately $374,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Metsera during the first quarter worth approximately $3,410,000.

Wall Street Analyst Weigh In

MTSR has been the topic of several recent research reports. Guggenheim lifted their target price on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a report on Tuesday, June 10th. Wells Fargo & Company assumed coverage on Metsera in a research note on Friday, June 20th. They set an "overweight" rating and a $65.00 target price for the company. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $55.00.

Metsera Stock Down 1.4%

Metsera stock traded down $0.46 during mid-day trading on Monday, hitting $32.59. The company's stock had a trading volume of 1,066,051 shares, compared to its average volume of 1,545,081. The firm's 50 day moving average is $33.42 and its 200 day moving average is $28.36. Metsera Inc. has a 52-week low of $12.30 and a 52-week high of $47.40.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings results on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.